C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Haruhito Azuma, Takuya Matsuda et al.|Targeted Oncology|2024Cited by 12
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan ConsortiumTaizo Uchimoto, Haruhito Azuma, Shogo Yamazaki et al.|International Journal of Clinical Oncology|2024Cited by 12
Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinomaTaizo Uchimoto, Haruhito Azuma, Tatsuo Fukushima et al.|British Journal of Urology|2022Cited by 10
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint InhibitorsTaizo Uchimoto, Haruhito Azuma, Shuya Tsuchida et al.|Targeted Oncology|2024Cited by 9
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortiumTaizo Uchimoto, Haruhito Azuma, Kengo Iwatsuki et al.|International Journal of Clinical Oncology|2025Cited by 4